Debu Tripathy on Genetic Risks for Breast Cancer
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses genetic risk for breast cancer, the strongest factor in determining if an individual will develop the disease.
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses genetic risk for breast cancer, the strongest factor in determining if an individual will develop the disease.
Tripathy emphasizes that patients with a strong family history or who develop breast cancer at a young age should be tested for gene mutations linked to breast cancer, such as BRCA1 and BRCA2 . However, despite an increasing ability to detect these mutations due to improvements in DNA sequencing, Tripathy says that doctors should not over-test people that don’t need it, as the results may be hard to interpret.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
